Organogenesis Provides Update on Phase 3 Renu® Study
Organogenesis reported that its second Phase 3 randomized controlled trial of ReNu, a cryopreserved amniotic suspension allograft for symptomatic...
AI Drug Discovery AstraZeneca BIO-Europe Spring 2026 biopharma M&A biopharma strategy biotech funding biotech strategy business development cancer immunotherapy China Biotech CNS Pipeline Strategy competitive intelligence Disease-Modifying Therapy Drug Pricing Strategy eClinical Tech News Eli Lilly Emerging Markets FDA Approval FDA Priority Review HER2 Oncology immuno-oncology immunology licensing deals Lifecycle Management Market Access Medtronic MSS colorectal cancer Novo Nordisk Obesity/GLP-1 Obesity Drug Market Obesity Market Oncology Pipeline Patent Cliff Priority Review Voucher pulmonary hypertension Rare Disease Regeneron respiratory biologics Roche Sanofi series A funding Teva Pharmaceuticals Type 1 Diabetes Type 2 Diabetes venture capital
No videos found.
Organogenesis reported that its second Phase 3 randomized controlled trial of ReNu, a cryopreserved amniotic suspension allograft for symptomatic...
Kraig Biocraft Laboratories has opened a second Southeast Asian rearing center for its engineered silkworms, bringing parallel production online...
BioXcel Therapeutics reported that its pivotal Phase 3 SERENITY at-home study met its primary endpoint, demonstrating that a 120...
Quell Therapeutics has convened a new scientific advisory board to steer its engineered T-regulatory cell therapy portfolio, adding heavyweight...
Seres Therapeutics will present a company overview at the H.C. Wainwright Global Investment Conference in New York on September...
Mesoblast will host a webcast to review operational highlights and full-year results for the period ended June 30, 2025,...
MediciNova has completed target enrollment in COMBAT-ALS, its Phase 2b/3 clinical trial of MN-166 (ibudilast), across sites in the...
Mesoblast has closed its fiscal year with the first FDA-approved mesenchymal stromal cell therapy on the U.S. market and...
Codexis will present at the Cantor Global Healthcare Conference in New York on September 4, 2025, with a webcast...
CytomX Therapeutics will participate in three high-profile investor conferences in New York this September, including Cantor’s Global Healthcare Conference,...
